| Sign In to gain access to subscriptions and/or personal tools. |
Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin converting enzyme inhibitors and aortic rupture: population based case control study. Lancet. 2006;368:659-665Cardiovascular Research Center University of Kentucky Lexington, Kentucky
Graduate Center for Nutritional Sciences University of Kentucky Lexington, Kentucky Background: Angiotensin-converting enzyme (ACE) inhibitors prevent the expansion and rupture of aortic aneurysms in animals. We investigated the association between ACE inhibitors and rupture in patients with abdominal aortic aneurysms. Methods: We did a population-based case-control study of linked administrative databases in Ontario, Canada. The sample included consecutive patients older than 65 (n = 15 326) admitted to hospital with a primary diagnosis of ruptured or intact abdominal aortic aneurysm between April 1, 1992, and April 1, 2002.
Findings: Patients who received ACE inhibitors before admission were significantly less likely to present with ruptured aneurysm (odds ratio [OR] 0.82, 95% CI 0.74—0.90) than those who did not receive ACE inhibitors. Adjustment for demographic characteristics, risk factors for rupture, comorbidities, contraindications to ACE inhibitors, measures of health-care use, and aneurysm screening yielded similar results (0.83, 0.73—0.95). Consistent findings were noted in subgroups at high risk of rupture, including patients older than 75 years and those with a history of hypertension. Conversely, such protective associations were not observed for ß blockers (1.02, 0.89—1.17), calcium channel blockers (1.01, 0.89—1.14), Interpretation: ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted.
Key Words: ACE inhibitor abdominal aortic aneurysm matrix metalloproteinase database analysis
Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 19, No. 3,
342-344 (2007) |
|||
blockers (1.15, 0.86—1.54), angiotensin receptor blockers (1.24, 0.71—2.18), or thiazide diuretics (0.91, 0.78—1.07).